Mucopolysaccharidosis type II (MPS II, Hunter disease) is an X chromosome-linked 
inherited metabolic disease caused by mutations resulting in deficiency of 
activity of iduronate-2-sulfatase (IDS) and accumulation of undegraded 
glycosaminoglycans (GAGs), heparan sulfate, and dermatan sulfate. Previous 
experiments with cell cultures and studies on animal model of MPS II suggested 
that gene expression-targeted isoflavone therapy (GET IT), based on 
genistein-mediated reduction of efficiency of GAG synthesis, might be a suitable 
therapy for this disease. In this report, we demonstrate efficacy of GET IT in 
connective tissue elasticity, particularly in improving the range of joint 
motion in seven patients with MPS II after 26 weeks of treatment with an 
isoflavone extract at the dose corresponding to 5 mg/kg/day of genistein.